The second phase III trial (Checkmate-7FL) randomized 510 early-stage (stage II-III, G3 with ER ≥ 1% or grade 2 with ER 1–10%) ER+/HER2− BC patients to standard NACT plus nivolumab or placebo. This evidence concerns the gene ERBB2 and breast cancer.